Acquired hemophilia
MONDO:0019139Acquired hemophilia is a bleeding disorder that interferes with the body's blood clotting process. Signs and symptoms include prolonged bleeding, frequent nosebleeds, bruising throughout the body, solid swellings of congealed blood (hematomas), hematuria, and gastrointestinal or urologic bleeding. Acquired hemophilia occurs when the body's immune system attacks and disables a certain protein that helps the blood clot. About half of the cases are associated with other conditions, such as pregnancy, autoimmune disease, cancer, skin diseases, or allergic reactions to medications.
Also known as: acquired hemophilia, hemophilia, acquired
19 clinical trials for this condition and its sub-types, 2 tagged with Acquired hemophilia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Acquired hemophilia
-
Acquired hemophilia A 5 trials
-
Acquired factor XI deficiency 0 trials
-
Acquired hemophilia B 0 trials
-
Battlefield plasma goes civil: can a powder save trauma victims?
Disease control CompletedThis study tested a freeze-dried plasma product that can be mixed with water in 6 minutes, avoiding the long thaw time of standard plasma. It included 42 trauma patients with severe bleeding who needed blood transfusions. The goal was to see if faster plasma delivery could improv…
Phase 3 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for rare bleeding disorder: which drug combo works best?
Disease control CompletedThis study tested two drug combinations in 110 adults with acquired hemophilia, a rare condition where the immune system attacks clotting factors, causing severe bleeding. One group received steroids plus cyclophosphamide, the other steroids plus rituximab. The goal was to see wh…
Phase 3 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for rare bleeding disorder: Single-Dose rituximab may replace daily chemo
Disease control CompletedThis study tested two treatments for acquired hemophilia A, a rare condition where the immune system attacks clotting factor VIII. 66 adults received either steroid plus a single dose of rituximab or steroid plus daily cyclophosphamide. The goal was to see which combination clear…
Phase 4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New blood product could cut transfusions in major surgeries
Disease control CompletedThis study tested a pathogen-reduced version of cryoprecipitate, a blood product that helps blood clot, in 208 patients undergoing liver transplant or heart surgery. The goal was to see if having this product readily available could stop bleeding early and reduce the need for oth…
Phase 4 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC